AbbVie Ready To Leverage Migraine Franchise In Crowded Market
Qulipta Adds Indication Not Covered By Botox, Ubrelvy
The US FDA approved the oral CGRP inhibitor Qulipta (atogepant) for migraine prevention, making AbbVie the only company with three drugs for three different migraine indications.
